Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami Beach on April 19 for a full day of networking and education.

Benzinga · Apr 25, 2022

Asthma drug can block crucial SARS-CoV-2 protein, says IISc

BENGALURU: Indian Institute of Science on Monday said a drug used to treat asthma and allergies can bind to and block a crucial protein produced by SARS-CoV-2 — the virus causing Covid-19 — and reduce viral replication in human immune cells.

The Times of India · Apr 25, 2022

FDA Gives Green Signal To Human Trial For Sorrento's STI-9167 Against Omicron

The FDA has cleared Sorrento Therapeutics Inc's (NASDAQ:SRNE) investigational new drug application (IND) for intravenous (IV) STI-9167 (COVISHIELD) to study the safety and pharmacokinetics in healthy volunteers. STI-9167 is the IV formulation of the intranasal STI-9199 neutralizing antibody. Also Read: Sorrento To Start Late-Stage Trial Of Abivertinib In Critically-Ill COVID-19 Patients. The Phase 1 study…

Benzinga · Apr 25, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Asthma drug can block crucial SARS-CoV-2 protein: IISc study

The study found that montelukast can reduce viral replication in human immune cells

The Hindu · Apr 25, 2022

COVID-19 breath tests could be the future of living with the virus, but this pandemic solution has a catch

The US has just approved a new COVID-19 breathalyser test that promises to deliver results within minutes, with no nasal swabs required. Scientists say it could help safeguard big gatherings from becoming superspreader events, but there are still a few kinks to iron out.

ABC News · Apr 25, 2022

Monitoring Board Gives Positive Recommendation On Ocugen's Eye Disease Gene Therapy Trial

The independent Data and Safety Monitoring Board (DSMB) for Ocugen Inc's (NASDAQ:OCGN) Phase 1/2 trial of OCU400 has recommended that the study proceeds with enrolling additional subjects. The recommendation follows the review of safety data based on dosing to date. OCU400 is the Company's flagship modifier gene therapy candidate for Retinitis Pigmentosa (RP)…

Benzinga · Apr 25, 2022

34 Stocks Moving In Monday's Mid-Day Session

Gainers Nkarta, Inc. (NASDAQ: NKTX) shares jumped 108.6% to $16.21 after the company announced Phase 1 data from independent dose finding studies of its two lead chimeric antigen receptor natural killer cell therapy candidates, NKX101 and NKX019.

Benzinga · Apr 25, 2022

Read news from The Economist, FT, and more,
with one subscription

Why Ardelyx Shares Are Rising

Ardelyx Inc (NASDAQ: ARDX) shares are trading higher by 29.32% at $0.97 after the company reported it received an interim response from the OND, CDER and FDA for the company’s second level of appeal of the Complete Response Letter for XPHOZAH.

Benzinga · Apr 25, 2022

Axsome Poised To Receive FDA Rejection For Its Migraine Candidate, Shares Fall

The FDA has informed that Axsome Therapeutics Inc (NASDAQ:AXSM) chemistry, manufacturing, and controls issues identified during the review of AXS-07 remain unresolved. The Company is seeking approval for AXS-07 for the acute treatment of migraine. Based on the time remaining in the review cycle, the Company expects to receive a Complete Response Letter…

Benzinga · Apr 25, 2022

Mid-Morning Market Update: Markets Open Lower; Dow Tumbles Over 300 Points

U.S. stocks opened lower this morning, with the Dow Jones dropping more than 300 points on Monday.

Benzinga · Apr 25, 2022

Why Axsome Therapeutics Stock Is Falling Today

Axsome Therapeutics Inc (NASDAQ: AXSM) shares are trading higher Monday after the company reported it was informed by the U.S.

Benzinga · Apr 25, 2022

FIR against online portal in Thane for selling abortion drugs

NAVI MUMBAI: A medical inspector attached to office of joint commissioner, Food and Drug Administration (FDA), Thane, on Saturday registered an FIR against Meesho, an online shopping portal, and M/s SS Traders, a medicine distributor based in Delhi, for selling abortion drugs online without doctor's prescriptions.

The Times of India · Apr 25, 2022

Three Cabinet and two shadow ministers are reportedly facing sexual misconduct claims

They are among 56 MPs to be referred to a parliamentary conduct watchdog, The Sunday Times said

Evening Standard · Apr 24, 2022

Three Cabinet ministers reported for sexual misconduct, according to report

They are among 56 MPs to be referred to a parliamentary conduct watchdog, The Sunday Times said.

The Independent UK · Apr 23, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK · Apr 23, 2022

Rees-Mogg criticised for leaving ‘crass’ messages in empty Whitehall offices

The minister has left notes for civil servants working from home telling them he is ‘looking forward’ to seeing them back in the office.

StockNews.com · Apr 22, 2022

Looking for Value Stocks to Add to Your Portfolio? Here are 5 For Your List

Heightened inflationary pressure, deepening supply chain disruptions, and the possibility of aggressive interest rate hikes later this year have fostered a volatile stock market. Because these factors are not expected to abate anytime soon, we think investors looking to generate solid long-term returns could consider betting on the stocks of…

Benzinga · Apr 22, 2022

60 Biggest Movers From Yesterday

Gainers Cyngn Inc. (NASDAQ: CYN) shares jumped 96.3% to close at $2.12 on Thursday after the company announced the official launch of DriveMod Kit, a turnkey autonomous vehicle solution.

Benzinga · Apr 21, 2022

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines

Revance Therapeutics, Inc. (NASDAQ: RVNC) announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) of its drug candidate DaxibotulinumtoxinA for Injection for the treatment of patients with moderate to severe glabellar lines.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Apr 21, 2022

FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs

The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.

Benzinga · Apr 21, 2022

Mid-Afternoon Market Update: Nasdaq Down 200 Points; United Airlines Shares Jump

U.S. stocks turned lower toward the end of trading, with the Nasdaq dropping 200 points on Thursday.

StockNews.com · Apr 21, 2022

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…

Benzinga · Apr 21, 2022

Mid-Day Market Update: Nasdaq Turns Negative; US Weekly Jobless Claims Edge Lower

U.S. stocks pared gains midway through trading, with the Nasdaq Composite dropping around 50 points on Thursday.

Benzinga · Apr 21, 2022

30 Stocks Moving In Thursday's Mid-Day Session

Gainers Swvl Holdings Corp. (NASDAQ: SWVL) shares gained 34.3% to $5.72. Alpha Tau Medical Ltd. (NASDAQ: DRTS) shares climbed 19.3% to $10.62.

Benzinga · Apr 21, 2022

NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 Therapy

NRx Pharmaceuticals Inc (NASDAQ:NRXP) has filed a new Breakthrough Therapy designation request with the FDA for Zyesami focused on a subgroup of critical COVID-19 patients. The subgroup includes patients who were also treated with Gilead Sciences Inc's (NASDAQ:GILD) Veklury (remdesivir) in addition to aviptadil or placebo. The request includes safety data on approximately 750 patients…

Benzinga · Apr 21, 2022

FDA Clears Moleculin's IND Application To Conduct Phase 1 Study Of WP1066 For Recurrent Malignant Glioma

Moleculin Biotech, Inc. (NASDAQ: MBRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application of the drug candidate WP1066 for Recurrent Malignant Glioma.

1 … 294 295 296 297

Coverage From

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.